Target intelligence / Profile preview

Endoplasmic reticulum-Golgi intermediate compartment 53 kDa protein (LMAN1)

Target
LMAN1
Molecular classification
Lectin, Cargo receptor, Membrane protein, Other (Secretory pathway protein)
01

Overview

Endoplasmic reticulum-Golgi intermediate compartment 53 kDa protein (LMAN1, also known as ERGIC-53) is a type I integral membrane mannose-specific lectin cycling between the endoplasmic reticulum (ER), the ER-Golgi intermediate compartment (ERGIC), and cis-Golgi. It functions as a cargo receptor for the ER-to-Golgi transport of selected glycoproteins, including blood clotting factors V and VIII, by forming a complex with MCFD2. Loss-of-function mutations result in combined deficiency of coagulation factors V and VIII, an autosomal recessive bleeding disorder. LMAN1 has also been implicated in colorectal tumorigenesis through early mutational inactivation. Its mechanism involves a calcium-dependent, pH-sensitive carbohydrate recognition domain, and it is not a direct target of any approved therapeutic drugs.

Other names
ERGIC-53Protein ERGIC-53Lectin, mannose-binding 1Intracellular mannose-specific lectin MR60MR60F5F8Dgp58Endoplasmic reticulum-Golgi intermediate compartment protein 53ER-Golgi intermediate compartment 53 kDa proteinLectin mannose-binding 1
02

Mechanism of action

Not drug-targeted directly; mutations in LMAN1 disrupt ER-to-Golgi transport of clotting factors V and VIII, leading to combined deficiency (loss of function).

03

Biological functions

Glycoprotein transportCargo receptor in ER-to-Golgi traffickingProtein sortingProtein N-linked glycosylationBlood coagulation (indirect, through transport of clotting factors V and VIII)
04

Disease associations

Combined deficiency of factor V and factor VIIICoagulation disordersCancer (LMAN1 inactivation potentially contributing to colorectal tumorigenesis)
05

Safety considerations

No direct therapeutic use or targeting, but genetic deficiency causes bleeding disorders due to factor V and VIII deficiency
06

Interacting drugs

None established as approved drugs directly modulating LMAN1; its main disease association is with inherited coagulation disorders rather than direct pharmacologic targeting
07

Biomarkers

LMAN1 mutation status (for diagnosis of inherited combined factor V and VIII deficiency)

Beyond the preview

Go deeper on Endoplasmic reticulum-Golgi intermediate compartment 53 kDa protein (LMAN1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Endoplasmic reticulum-Golgi intermediate compartment 53 kDa protein (LMAN1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call